PMC:7650537 / 19239-20231 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T132","span":{"begin":247,"end":250},"obj":"Body_part"},{"id":"T133","span":{"begin":964,"end":967},"obj":"Body_part"}],"attributes":[{"id":"A132","pred":"fma_id","subj":"T132","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A133","pred":"fma_id","subj":"T133","obj":"http://purl.org/sig/ont/fma/fma62872"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":508,"end":513},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T94","span":{"begin":236,"end":244},"obj":"Disease"},{"id":"T95","span":{"begin":302,"end":310},"obj":"Disease"},{"id":"T96","span":{"begin":313,"end":322},"obj":"Disease"},{"id":"T97","span":{"begin":558,"end":566},"obj":"Disease"},{"id":"T98","span":{"begin":692,"end":700},"obj":"Disease"},{"id":"T99","span":{"begin":765,"end":773},"obj":"Disease"},{"id":"T100","span":{"begin":953,"end":961},"obj":"Disease"}],"attributes":[{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T160","span":{"begin":77,"end":82},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T161","span":{"begin":188,"end":193},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T162","span":{"begin":291,"end":292},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T163","span":{"begin":347,"end":348},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T164","span":{"begin":369,"end":372},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T165","span":{"begin":459,"end":460},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T166","span":{"begin":616,"end":620},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T167","span":{"begin":672,"end":673},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T168","span":{"begin":828,"end":829},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}

{"project":"LitCovid-sentences","denotations":[{"id":"T156","span":{"begin":0,"end":143},"obj":"Sentence"},{"id":"T157","span":{"begin":144,"end":323},"obj":"Sentence"},{"id":"T158","span":{"begin":324,"end":399},"obj":"Sentence"},{"id":"T159","span":{"begin":400,"end":531},"obj":"Sentence"},{"id":"T160","span":{"begin":532,"end":635},"obj":"Sentence"},{"id":"T161","span":{"begin":636,"end":877},"obj":"Sentence"},{"id":"T162","span":{"begin":878,"end":992},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}

{"project":"LitCovid-PubTator","denotations":[{"id":"343","span":{"begin":219,"end":220},"obj":"Gene"},{"id":"344","span":{"begin":225,"end":226},"obj":"Gene"},{"id":"345","span":{"begin":578,"end":586},"obj":"Species"},{"id":"346","span":{"begin":692,"end":702},"obj":"Species"},{"id":"347","span":{"begin":765,"end":775},"obj":"Species"},{"id":"348","span":{"begin":236,"end":246},"obj":"Species"},{"id":"349","span":{"begin":953,"end":963},"obj":"Species"},{"id":"350","span":{"begin":302,"end":322},"obj":"Disease"},{"id":"351","span":{"begin":558,"end":577},"obj":"Disease"}],"attributes":[{"id":"A343","pred":"tao:has_database_id","subj":"343","obj":"Gene:43740575"},{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"Gene:43740568"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"Tax:9606"},{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"Tax:2697049"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"Tax:2697049"},{"id":"A348","pred":"tao:has_database_id","subj":"348","obj":"Tax:2697049"},{"id":"A349","pred":"tao:has_database_id","subj":"349","obj":"Tax:2697049"},{"id":"A350","pred":"tao:has_database_id","subj":"350","obj":"MESH:C000657245"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Here, we analyzed the diagnostic performance of eight commercially available tests, all of which have been released within the past few months. These were compared to identify appropriate tests to study the kinetics of N- or S-specific SARS-CoV-2 IgG or total antibodies in outpatients with a previous SARS-CoV-2 infection. To our knowledge, such a comprehensive study has not been conducted before. Three assays (Abbott, DiaSorin, and Roche) were applied in a random-access manner, which reduced the needed hands-on-time markedly. Convalescent sera from 26 SARS-CoV-2-infected patients were used to investigate the test sensitivities. These samples were characterized by a previous positive SARS-CoV-2 PCR result of the donors (reference method 1) and may possess SARS-CoV-2-neutralizing capacities (\u003e1:10), as demonstrated in a laboratory-developed PRNT (reference method 2). Furthermore, two versions of an immunoblot, including the determination of SARS-CoV-2 IgG avidities, were applied."}